Hereditary Hemochromatosis (HH) is a genetically heterogeneous disorder caused by mutations in at least five different genes (HFE, HJV, TFR2, SLC40A1, HAMP) involved in the production or activity of the liver hormone hepcidin, a key regulator of systemic iron homeostasis. Nevertheless, patients with an HH-like phenotype that remains completely/partially unexplained despite extensive sequencing of known genes are not infrequently seen at referral centers, suggesting a role of still unknown genetic factors. A compelling candidate is Bone Morphogenetic Protein 6 (BMP6), which acts as a major activator of the BMP-SMAD signaling pathway, ultimately leading to the upregulation of hepcidin gene transcription. A recent seminal study by French authors has described three heterozygous missense mutations in BMP6 associated with mild to moderate lateonset iron overload (IO). Using an updated next-generation sequencing (NGS)-based genetic test in IO patients negative for the classical HFE p.Cys282Tyr mutation, we found three BMP6 heterozygous missense mutations in four patients from three different families. One mutation (p. Leu96Pro) has already been described and proven to be functional. The other two (p.Glu112Gln, p.Arg257His) were novel, and both were located in the pro-peptide domain known to be crucial for appropriate BMP6 processing and secretion. In silico modeling also showed results consistent with their pathogenetic role. The patients' clinical phenotypes were similar to that of other patients with BMP6-related IO recently described. Our results independently add further evidence to the role of BMP6 mutations as likely contributing factors to late-onset moderate IO unrelated to mutations in the established five HH genes.
increased hepcidin expression. 9 In animal models, several pieces of evidence suggest a prominent role of BMP6 in the regulation of iron homeostasis. 10 In wild-type mice fed with diets of different iron content, liver BMP6 expression correlates with body iron stores and with
Hamp1 transcription. 11, 12 Moreover, BMP6-deficient mice exhibit a phenotype resembling HH, with an inappropriately low level of hepcidin and tissue iron overload, 13, 14 while injection of BMP6 is able to rescue Hamp1 expression. 14 According to the currently accepted model, BMP6 is produced mainly by nonparenchymal liver cells 15 in response to sensing of iron stores in order to adjust hepcidin production to body needs. 3 In contrast to the observations in BMP6-deficient mice, direct evidence of a human genetic counterpart has remained elusive until last year, when
Daher and colleagues first reported three heterozygous mutations in BMP6 in patients with late-onset IO from five unrelated families. 16 All of the mutations involved the BMP6 prodomain, which is known to be crucial for proper BMP6 processing and secretion, and showed a dominant negative effect. This was elegantly explained by showing the intracellular retention of BMP6 heterodimers composed from wildtype and mutated proproteins. 16 Indeed, BMP6 needs to assemble as a dimer to fully exert its extracellular function in the iron-sensing machinery. 17 In the present study, we describe four IO patients carrying 3 heterozygous missense mutations in the prodomain region of BMP6 gene, two of which are novel. These findings contribute evidence supporting a role of BMP6 mutations as genetic factors predisposing to human IO.
| M E T H O D S

| Patients
Our recently described Next-Generation Sequencing (NGS)-based test
for IO disorders, 6 updated to include the BMP6 gene (see below for details), was applied to 37 probands (mean age 51. , and SLC40A1), was performed according to our previously described method. 6 Briefly, capture of genomic regions was performed starting from 225 ng of gDNA using a custom design HaloPlex Data analysis and variant validation was performed as previously described. 6 Genomic regions containing the variants of interest were amplified by conventional PCR, and the three BMP6 mutations were confirmed in all four patients by Sanger sequencing.
| Sequence alignment and in silico modeling
Pro-BMP6 sequences from different species were retrieved from UNIPROT 18 and aligned using the MUSCLE program 19 for multiple alignments. Conservation analysis and alignment visualization was performed by Jalview software 20 (Supporting Information Figure S1 ).
Homology modeling techniques were employed to build the BMP6 dimer, using the SwissDock server. 21 TGF-b1 (PDB code: 3RJR) was used as a template. The dimer modeling option was chosen. The generated models were evaluated by using the qmean potential. The best one was then energy-minimized by using Chimera software (http:// www.cgl.ucsf.edu/chimera/); the AMBER ff14SB tool 22 was used to perform 100 and 1000 steps of steepest descent and conjugate gradients algorithms, respectively. The positions of the variants in the modeled structure of BMP6 were mapped by Chimera, which was also used to generate the images.
| Hepcidin measurement
Hepcidin analysis was performed using an updated and validated
Mass-Spectrometry (MS)-based assay, which was able to dissect the iron bioactive hepcidin-25 from other hepcidin isoforms. 23 We used a liquid chromatography-tandem mass spectrometry (LC-MS/MS) approach. 24 Briefly, hepcidin-25 synthetic standards (the native and the isotopic labeled internal standard), as well as standards for hepcidin-20 and hepcidin-24 isoforms, were purchased from Peptide
International (Lousiville, USA). An internal standard was added in all samples, and the calibration curve created. Blank serum (deprived of hepcidin by using charcoal treatment) was used as a reference. Samples were treated by solid-phase extraction using Oasis hydrophiliclipophilic balanced reversed-phase (HLB) cartridges (Waters, Italia).
High performance LC was performed using an X-Terra MS C 18 2.5 mm column (Waters, Italia), and detection was obtained using a Triple Quad LC-MS/MS (Agilent Technologies). The results were evaluated according to previously obtained reference ranges for males and females at different ages (Table 1) . 25 
| R E S U L T S 3.1 | BMP6 mutations and in silico modeling
Our NGS-based test detected 3 different heterozygous pro-BMP6 mutations in the probands. Concurrently, no further potentially pathogenic variant was found in the five canonical HH genes (HFE, HJV, HAMP, TFR2, and SLC40A1), with the exception of the already mentioned p.His63Asp on HFE in patients #01 and #03.
Of note, one BMP6 mutation (rs200573175, NM_001718.4:
c.287T > C, p.Leu96Pro), detected in patient #01, was the same mutation identified by Daher et al. 16 This mutation is located in exon 1 in the pro-peptide domain, is highly conserved (98%) across different species, and has already been demonstrated to be functional. 16 The other two BMP6 mutations were new. The p.Glu112Gln mutation conserved (Supporting Information Figure S1 ). According to a bioinfor- 28 We also checked for the presence of the three BMP6 variants in 111 Italian
Caucasian subjects with normal iron parameters from another cohort at our hospital. 29 We found two carriers of the p.Leu96Pro mutation (corresponding to an allele frequency of 0.009), while neither the p.
Arg257His mutation nor the p.Glu112Gln mutation were detected.
Our in silico modeling of the BMP6 dimer was built by homology, using the published solved structure of TGF-b1 as a template. 30 The predicted conserved secondary structural elements of the prodomains across members of the TGF-b ligands 31 allowed us to predict the putative localization and functional effects of the mutations detected, as illustrated in Figure 1 . The Leu96 and Glu112 amino acids are projected to be located in the latency lasso domain, which encircles the fingers of the opposing monomer, while Arg257 is located in the arm domain.
Leu96 is involved in a putative hydrophobic interaction with Leu99, and its replacement with Pro96 is predicted to cause bumps with nearby residues, creating local perturbations at the backbone level ( Figure 1A ). Glu112 is a negatively charged residue located near the dimerization interface, and its substitution with a neutral Gln112 residue may change the physicochemical (electrostatic) properties of this region, disrupting these interactions ( Figure 1B ). 32 Our in silico model is consistent with the cytoplasmic aggregation of BMP6 mutants observed by Daher et al. through immunolocalization in transfected cells. 16 Indeed, both p.Leu96Pro and p.Glu112Gln are located in the same amino acid cluster, in a key region clearly involved in the interaction between the two monomers ( Figure 1 ) and particularly conserved across the TGF-b superfamily. 31 The local perturbations created by these mutations likely affect this interaction, possibly leading to the formation of unfolded dimers that are subsequently degraded.
According to our model, Arg257 may belong to a network of ionic interactions, along with two glutamic acid residues (Glu307 and Glu255).
The substitution with a histidine residue could change the pH dependency of the region, altering the local stability. This region of the arm domain, enriched in charged amino acids, appears to be a common feature of TGF-b ligands and is reported to be involved in the interaction with extracellular matrix proteins. 31 Thus, its alteration could theoretically affect either assembly/secretion or final localization of BMP6. However, further experimental data would be needed to verify this hypothesis.
| Serum hepcidin
Hepcidin levels were markedly low in patients #01 and #03 (Table 1) .
Both patients could be considered in principle as double heterozygous since they also carried the p.His63Asp variant in HFE. Patients #02 and #04 showed slightly increased or normal hepcidin levels, respectively, which in both cases appeared inappropriately low for the iron overload. 33 
| DISCUSSION
Notwithstanding great advances in human iron pathophysiology, a number of molecular mechanisms remain to be clarified. 2 Progresses in   FIG URE 1 Structural analysis of variants mapped on the 3D model of human pro-BMP6. Homology modeling was performed on the solved structure of pro-TGF-b1. In the central part of the figure, three parts of the two pro-peptide monomers are identified with different colors: on the left, the prodomain arm and latency lasso are highlighted in cyan and orange, respectively; the corresponding mature BMP6 is shown in green. On the right, the arm and latency lasso are yellow and pink, respectively, and the related mature BMP6 is represented in red. The pop-up panels magnify the regions with the three identified variants (panel A for p.Leu96Pro, B for p.Glu112Gln, and C for p.Arg257His). In particular, panels A and B illustrate that the two variants are localized to a region in which the mature BMP6 of one monomer is enveloped by the latency lasso of the opposing prodomain. In C, the variant is localized to a solvent-exposed region of the arm domain the elucidation of these molecular pathways could help for diagnosis and treatment of patients affected by iron-related disorders, particularly those with IO in whom no causative mutation in the known HH genes can be identified. and hetero-dimers. 41 Regarding BMP6, the highly conserved prodomain region spanning from amino acids 96 to 113 appears particularly important for protein processing and secretion, 17 and mutations in this amino acid cluster (like the new p.Glu112Gln described in this paper) could be associated with intracellular protein retention. 16 Indeed, the latency lasso region in which these residues are localized appears fundamental for proper folding of the dimer (Figure 1) . Notably, at variance with other BMPs, BMP6 is secreted along with the prodomain, which is eventually cleaved in the extracellular matrix by a convertase (PACE4) associated with heparan sulfate proteoglycans. 42 The BMP6
prodomain by itself appears to have an important role in facilitating a
proper interaction with the extracellular matrix and the subsequent cleavage into the functionally mature peptide, 43 suggesting the potential pathogenicity of other amino acid substitutions not primarily affecting the protein secretion. For example, in our model, the p.Arg257His substitution, which is located in the arm region, could affect either folding or the interaction with extracellular matrix proteins. However, further experimental data (i.e., molecular biology and site-directed mutagenesis experiments) would be needed to verify these hypotheses.
In addition to molecular analogies, the clinical and biochemical features of our patients are also consistent with those observed by Daher and colleagues. 16 They concluded that BMP6 mutations were sufficient to explain mild to moderate late-onset IO in males characterized by unexplained hyperferritinemia, increased LIC, and variable transferrin saturation levels (normal to high). Moreover, based on their observations in patients with additional risk factors for IO, they postulated a role for BMP6 mutations in aggravating the accumulation of iron when common conditions such as metabolic syndrome 44 Cys282Tyr and the rare p.Glu277Lys). 38 Altogether, these observations agree with the hypothesis of an interaction between BMP6 and HFE, supported by animal models in which HFE deficiency has been shown to impair BMP6 signaling. 51, 52 The other two BMP6 patients in our series had absolute hepcidin levels either normal or only slightly elevated, i.e., in both cases inappropriately low in relation to the concomitant IO, as observed in the French series. 16 This resembles what has been observed in classical HFE-related HH, where normal or only slightly increased serum hepcidin levels, as well as inappropriately normal iron absorption, were reported despite the presence of excess liver iron. 33, [53] [54] [55] Overall, the hepcidin levels in the heterozygous BMP6
patients were all consistent with the implication of BMP6 pro-peptide mutations in defective iron signaling and an insufficient hepcidin response.
In summary, we report four additional IO patients carrying three BMP6 mutations, two of which are novel. All mutations were localized to the pro-peptide domain, and our modeling supports the hypothesis that the structural and/or electrostatic changes induced by the variants may affect production of the functional BMP6 mature peptide, leading to an inappropriate hepcidin response.
Our data appear to independently confirm BMP6 as a novel gene to be added to the list of mutant genes contributing to determining an 
